203 results
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
27 Feb 24
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
7:24am
special protocol assessment (SPA) feedback and positive results from the proposed trial. Aldeyra intends to include in the potential NDA resubmission
8-K
EX-10.1
m0xap3z qqefb8iw
17 Oct 23
Entry into a Material Definitive Agreement
7:24pm
8-K
EX-10.1
a9v5d
4 Nov 22
Unaudited Pro Forma Condensed Consolidated Financial Statements
4:08pm
S-3ASR
EX-1.2
1nf3wv b23x4c4e
30 Sep 22
Automatic shelf registration
4:17pm
425
EX-99.1
8r02t4nrd wc8egc
21 Jun 22
Business combination disclosure
8:00am
8-K
EX-99.1
9hqb1igivaz 2b2twqf
21 Jun 22
Regulation FD Disclosure
6:19am
425
na5f9yh9crn1
24 Mar 22
Business combination disclosure
9:09am
8-K
EX-2.1
x8i tu2k714
24 Mar 22
Entry into a Material Definitive Agreement
9:08am
8-K
EX-2.2
mo4kt00
24 Mar 22
Entry into a Material Definitive Agreement
9:08am
425
EX-99.2
3s2g9zpu
23 Mar 22
Business combination disclosure
5:29pm